Ribupatide
Intervention1 paper4 findings
In a human trial, ribupatide reduces body weight and fasting plasma glucose at 0.9–5.4 mg over four weeks. The same paper reports reduced body weight and food intake in mice over 28 days.
- Human trial1
Outcomes
3Body weight
downin humans1downin mice1Moderate certainty
1 study
Body weight
downin humans1downin mice1Moderate certainty
Ribupatide decreases body weight in humans (-4.3 kg (-6.7%) to -7.7 kg (-9.6%) vs -1.2 kg (-1.4%)).
Human trial0.9 to 5.4 mg4 weeks
Preclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist · Diabetes, obesity & metabolism · 20 Sep 2026
Ribupatide decreases body weight in mice.
Animals28 days
Preclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist · Diabetes, obesity & metabolism · 20 Sep 2026
Fasting plasma glucose
downin humans1Moderate certainty
1 study
Fasting plasma glucose
downin humans1Moderate certainty
Ribupatide decreases fasting plasma glucose in humans.
Human trial0.9 to 5.4 mg4 weeks
Preclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist · Diabetes, obesity & metabolism · 20 Sep 2026
Food intake
downin mice1Moderate certainty
1 study
Food intake
downin mice1Moderate certainty
Ribupatide decreases food intake in mice.
Animals28 days
Preclinical and First-In-Human Evaluation of Ribupatide (HRS9531), a Dual GLP-1/GIP Receptor Agonist · Diabetes, obesity & metabolism · 20 Sep 2026